Recent News

• 03.12.2025 - Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
• 03.10.2025 - Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
• 03.10.2025 - Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
• 03.07.2025 - Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Recent Filings

• 03.10.2025 - EX-99.1 EX-99.1
• 03.10.2025 - 8-K Current report
• 03.10.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities